Cargando…
Efficacy and Safety of Sevelamer Carbonate in Chinese Nondialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized, Double-Blind, Parallel-Group Study
INTRODUCTION: Previous studies suggested that sevelamer carbonate is well tolerated with a favorable efficacy and safety profile in both dialysis and nondialysis patients in Europe; however, the efficacy remains controversial, and few studies have examined sevelamer carbonate therapy in other ethnic...
Autores principales: | Chen, Wei, Liu, Hua-Feng, Chen, Qin-Kai, Zhao, Ming-Hui, Chen, Xiao-Nong, Liu, Hong, Wan, Jian-Xin, Li, Shao-Mei, Chen, Meng-Hua, Dai, Chun, Shi, Hong-Bin, Wei, Jia-Li, Zhao, Hong-Wen, Wang, Li-Hua, Long, Gang, Lu, Wan-Hong, Tang, Ying, Yang, Jun-Wei, Cao, Li-Ying, Tang, Dong-Xing, Yang, Yu-Qiong, Yu, Xue-Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10090999/ https://www.ncbi.nlm.nih.gov/pubmed/37065610 http://dx.doi.org/10.1159/000527833 |
Ejemplares similares
-
Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients
por: Zeng, Qian, et al.
Publicado: (2023) -
Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
por: Savica, Vincenzo, et al.
Publicado: (2008) -
Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China
por: Xu, Jing, et al.
Publicado: (2013) -
Sevelamer arsenite nanoparticle as a Pi-responsive drug carrier and embolic agent for chemoembolization
por: Bi, Qiu-Chen, et al.
Publicado: (2022) -
A Retrospective Single-Center Study of Sevelamer Hydrochloride for the Treatment of Hyperphosphatemia in Children With Tumor Lysis Syndrome
por: Al Blewi, Sawsan M, et al.
Publicado: (2023)